secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-08-10T11:49:17+00:00
Accession:  0001703057-26-000053
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Phase 2 ABCL635 meets endpoints: 83% cut in hot flash frequency vs 33% placebo
--------------------------------------------------------------------------------

- Phase 2 met primary endpoints: 8.8 mean reduction in daily moderate/severe hot flashes vs 3.5 placebo (p<0.001) at week 4 after single 600 mg dose
- Frequency fell 83% vs 33% placebo (50% placebo-adjusted); severity down 58% vs 12% (46% adjusted, p<0.001)
- 92 postmenopausal women enrolled, 1:1 randomized; improvements in sleep and PGI-C also significant
- No serious/severe AEs or discontinuations; common AEs: headache, fatigue, injection site reaction
- Company plans Phase 3 validation; CMO Sarah Noonberg cites potential best-in-class single-dose relief

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000053/0001703057-26-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000053/abcl-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001703057-26-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer